The mammalian target of rapamycin (mTOR) kinase is a critical regulator of mRNA translation and is known to be involved in various long lasting forms of synaptic and behavioural plasticity. However, information concerning the temporal pattern of mTOR activation and susceptibility to pharmacological intervention during both consolidation and reconsolidation of long-term memory (LTM) remains scant.
a b s t r a c t
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Male C57BL/6 mice were injected systemically with rapamycin at various time points following conditioning or retrieval in an auditory fear conditioning paradigm, and compared to vehicle (and/or anisomycin) controls for subsequent memory recall.
Systemic blockade of mTOR with rapamycin immediately or 12 h after training or reactivation impairs both consolidation and reconsolidation of an auditory fear memory. Further behavioural analysis revealed that the enduring effects of rapamycin on reconsolidation are dependent upon reactivation of the memory trace. Rapamycin, however, has no effect on short-term memory or the ability to retrieve an established fear memory.
Collectively, our data suggest that biphasic mTOR signalling is essential for both consolidation and reconsolidation-like activities that contribute to the formation, re-stabilization, and persistence of long term auditory-fear memories, while not influencing other aspects of the memory trace. These findings also provide evidence for a cogent treatment model for reducing the emotional strength of established, traumatic memories analogous to those observed in acquired anxiety disorders such as posttraumatic stress disorder (PTSD) and specific phobias, through pharmacologic blockade of mTOR using systemic rapamycin following reactivation.
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Introduction
Evidence for the role of protein synthesis as a definite property of memory consolidation has been demonstrated primarily through the use of protein synthesis inhibitors around the time of or in the first few hours following training (Cohen et al., 2006; Davis & Squire, 1984; Desgranges, Lévy, & Ferreira, 2008; Meiri & Rosenblum, 1998; Milekic, Pollonini, & Alberini, 2007) . Importantly, confirmation of this phenomenon has been very consistent across a variety of behavioural paradigms and species (Davis & Squire, 1984; McGaugh, 2000) . However, while protein synthesis dependency for long-term memory (LTM) formation has been well documented, more recent evidence suggests that there is at least a second wave of protein synthesis that is required for persistence of the engram under certain mnemonic conditions, hours after training (Bekinschtein, Cammarota, et al., 2007; Bourtchouladze et al., 1998; Freeman, Rose, & Scholey, 1995; Grecksch & Matthies, 1980; Quevedo et al., 1999) . In these studies at least two time periods of sensitivity to the amnesic effects of the global protein synthesis inhibitor anisomycin (ANISO) were confirmed, first around the time of training, and the second 3-5 (Bourtchouladze et al., 1998; Freeman et al., 1995; Grecksch & Matthies, 1980; Quevedo et al., 1999 ) or 12 h (Bekinschtein, Cammarota, et al., 2007 posttraining.
Elucidation of events upstream, related to the expression and regulation of protein synthesis, including signalling cascades and mRNA synthesis, have become critical in furthering our understanding of the neurobiology of learning and memory. Similar to protein synthesis, many of these substrates and cascades are amenable to pharmacological disruption (Bernabeu et al., 1997; Lee, Everitt, & Thomas, 2004; Trifilieff et al., 2006) . Moreover, these upstream events, such as increased mRNA expression, or the activation of signalling cascades and growth factors, for example Protein Kinase A (PKA) or Brain Derived Neurotrophic Factor (BDNF) appear to parallel the same biphasic kinetic pattern and susceptibility to pharmacological interventions as de novo protein synthesis in LTM formation and persistence (Bekinschtein, Cammarota, et al., 2007; Bernabeu et al., 1997; Bourtchouladze et al., 1998; Igaz, Vianna, 
